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The brain noradrenergic system supplies the neurotransmitter norepinephrine throughout
the brain via widespread efferent projections, and plays a pivotal role in modulating
cognitive activities in the cortex. Profound noradrenergic degeneration in Alzheimer’s
disease (AD) patients has been observed for decades, with recent research suggesting
that the locus coeruleus (where noradrenergic neurons are mainly located) is a
predominant site where AD-related pathology begins. Mounting evidence indicates
that the loss of noradrenergic innervation greatly exacerbates AD pathogenesis and
progression, although the precise roles of noradrenergic components in AD pathogenesis
remain unclear. The aim of this review is to summarize current findings on noradrenergic
dysfunction in AD, as well as to point out deficiencies in our knowledge where more
research is needed.
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Introduction
Noradrenergic neurons are located primarily in the locus coeruleus. Via wide spread efferent
projections, these neurons provide norepinephrine throughout the brain (Swanson and Hartman,
1975). Along with dopamine and epinephrine, norepinephrine is a catecholamine that is
synthesized through a series of enzymatic steps that begins with the amino acid tyrosine. Tyrosine
is first converted to levodopa (L-DOPA) by the enzyme tyrosine hydroxylase, which is the rate-
limiting step. Pyridoxal phosphate and DOPA decarboxylase then convert L-DOPA to dopamine,
which is subsequently converted to norepinephrine by dopamine beta hydroxylase (DβH).
After synthesis, norepinephrine is released by presynaptic noradrenergic terminals, and can
bind to receptors, be degraded by enzymes such as catechol-O-methyltransferases (COMT) or
monoamine oxidases (MAO) (Golan et al., 2011), or undergo reuptake into the presynaptic
neuron. Norepinephrine elicits its effects through three classes of adrenergic receptors, the α1,
the α2, and the β adrenergic receptors, each of which consists of three subtypes (Hein, 2006).
While all of the receptors are located at postsynaptic neurons, the α2 receptors are uniquely
also located presynaptically where they function as autoreceptors to inhibit the further release of
norepinephrine (Knaus et al., 2007). The amount of norepinephrine available to bind to receptors
is largely dependent on either degradation or reuptake of norepinephrine to the presynaptic
terminals. Norepinephrine reuptake is mediated by the norepinephrine transporter, a Na/K pump
that returns norepinephrine to the presynaptic terminal.
Changes in the noradrenergic system have long been observed in Alzheimer’s disease (AD).
Pathological changes of noradrenergic neurons in the locus coeruleus, including the accumulation
of tau protein (Braak and Del Tredici, 2012), begin early in the progression of AD. Later in the
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disease, profound loss of the noradrenergic neurons is observed,
along with compensatory changes such as modifications
of neuronal anatomy, neurotransmitter, and noradrenergic
receptors. Given the well-established functions of the
noradrenergic system in cognition, neuroinflammation,
and metabolism, it could be predicted that noradrenergic
dysfunction in AD would promote disease progression. Indeed,
evidence from both human patients and animal models indicates
that loss of noradrenergic innervation greatly exacerbates AD
pathogenesis and progression (Marien et al., 2004; Heneka et al.,
2006; Grudzien et al., 2007; Kalinin et al., 2007; Pugh et al.,
2007). There is currently no effective treatment or cure for AD.
Understanding the changes that occur in the noradrenergic
system in AD patients could present a unique opportunity to
inspire new avenues of treatment. The purpose of this review
is to describe what is currently known about noradrenergic
dysfunction in AD and its potential contribution to AD
pathology and progression, as well as to point out deficiencies in
our knowledge where more research is needed.
The Role of the Noradrenergic System in
Cognition
The role of the noradrenergic system on cognition has been
reviewed extensively elsewhere (Chamberlain and Robbins,
2013). We provide a brief overview of the literature here as an
introduction to the role of the noradrenergic system in AD, but
we are aware that we have not mentioned all relevant papers to
this topic.
Importance of Norepinephrine
Examining the effects of norepinephrine depletion has revealed
the importance of norepinephrine in cognitive tasks. Depletion
of norepinephrine in animal and cellular models has been
achieved in three different ways. First, norepinephrine depletion
has been accomplished through degeneration of noradrenergic
neurons with DSP-4, a neurotoxin selective for noradrenergic
neurons. While this most completely depletes norepinephrine,
it also causes structural changes in the brain and therefore
the changes may not necessarily be completely attributed to
the neurotransmitter loss. Another method of norepinephrine
depletion is the use of reserpine to block the vesicular
monoamine transporter (VMAT), which transports monoamines
into vesicles in the presynaptic terminal for synaptic release.
It is important to note that reserpine is not specific to
norepinephrine and works on all monoamines, including
dopamine and serotonin. A final method of norepinephrine
depletion is through the knockout of DβH (the enzyme
converting dopamine to norepinephrine) to look exclusively at
the effects of norepinephrine. Despite of the potential limitation
associated with each method, studies with these independent
methods have demonstrated that loss of norepinephrine leads to
cognitive impairment in various aspects of cognition.
Depletion of norepinephrine in rats by DSP-4 leads to deficits
in working memory (Sontag et al., 2008). This deficit has also
been shown to be exacerbated when in combination with the
depletion of other neurotransmitters, either dopamine (Pérez
et al., 2009) or acetylcholine (Ohno et al., 1997). Treating
monkeys with reserpine also induces a working memory deficit
(Cai et al., 1993). Deficits in spatial memory, as measured
by the Morris water maze, have also been reported following
norepinephrine depletion with DSP-4, and this effect is especially
significant in stressed and aged rats (Sirviö et al., 1991; Lapiz
et al., 2001). In addition, DSP treatment impairs visual memory
(Rajabi et al., 2012), olfactory memory (Guan et al., 1993)
and avoidance learning, and administration of epinephrine
rescues the avoidance learning defect caused by norepinephrine
depletion (Bennett et al., 1990). DβH deficient mice also show
impaired active-avoidance learning (Thomas and Palmiter, 1997)
and social memory (Marino et al., 2005). Together, these studies
strongly support a critical role of norepinephrine in cognitive
functions.
An alternate method of studying the effect of norepinephrine
on cognition is by increasing the availability of this
neurotransmitter. The selective norepinephrine reuptake
inhibitor atomoxetine increases the amount of norepinephrine
available in the synapse by preventing its reuptake by the
presynaptic terminals. Increasing norepinephrine improves
spatial learning and memory of rats in both the novel object
task and the radial arm maze (Tzavara et al., 2006). Additionally,
improvements in working memory (Gamo et al., 2010) and
attention (Tzavara et al., 2006; Jentsch et al., 2009) have been
seen after atomoxetine treatment. These results are consistent
with the findings from the depletion studies; while a decrease
in norepinephrine induces cognitive deficits, increasing
norepinephrine can improve cognitive function.
Differential Roles of the Adrenergic Receptors
All nine adrenergic receptors are members of the G-protein
coupled receptor family. The α1 receptors all signal through
the Gq signaling pathway and cause increases in both IP3 and
calcium upon activation (Chen and Minneman, 2005; Perez,
2007). The β receptors all signal through the Gs signaling
pathway and activation of these receptors leads to increased
cAMP. The β2 receptor is also able to signal through the Gi
signaling pathway to modulate cAMP and lead to ERK activation
(Hall, 2004; Xiang, 2011). The α2 receptors signal through
the Gi/o signaling pathway to inhibit both calcium and cAMP
(Knaus et al., 2007). The α2 receptors can serve as autoreceptors
on presynaptic noradrenergic terminals, inhibiting the further
release of norepinephrine. The known functions of different
adrenergic receptors in cognition are summarized in Table 1.
The α1 receptor has been investigated in both fear
conditioning and spatial learning. Overall, inhibition of the
α1 receptor impairs learning while activation of the receptor
improves it. In fear learning, antagonism of the α1 receptor leads
to poorer performance in these tasks. Prazosin, an α1antagonist,
has been shown to cause both a diminished fear response in
an olfactory fear conditioning paradigm (Do Monte et al.,
2013) and in an olfactory recall task (Veyrac et al., 2007). In
spatial learning, prazosin induces impairment (Torkaman-
Boutorabi et al., 2014) and also exacerbates a deficit induced
by scopolamine, a muscarinic cholinergic antagonist (Puumala
et al., 1998). Consistent with the antagonist data, treatment
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TABLE 1 | The known functions of adrenergic receptors in cognition.
Receptor Subtype Function in cognition Localization of
function
α1 α1A Improve spatial learning (Doze
et al., 2011)
Hippocampus
α1B Improve fear learning (Nalepa
et al., 2013)
Amygdala
α1D Improve working memory and
attention (Mishima et al., 2004)
Prefrontal cortex
α2 α2A Impair spatial and fear learning
(Gamache et al., 2012; Warner
and Drugan, 2012; Zoladz et al.,
2013; Torkaman-Boutorabi
et al., 2014)
Hippocampus
Improve working memory
(Arnsten and Goldman-Rakic,
1985, 1987; Arnsten et al.,
1988)
Prefrontal cortex
α2B Unknown –
α2C Unknown –
β β1 Improve auditory fear memory
(Qu et al., 2008)
Administration into
amygdala
Impair spatial reference memory Hippocampus
β2 Improve memory retrieval
(Introini-Collison et al., 1991)
Administration into
amygdala
Improves fear memory (Zhou
et al., 2013)
Administration into
prefrontal cortex
Improve auditory fear memory
(Qu et al., 2008)
Administration into
amygdala
β3 unknown –
with α1agonists has been shown to improve spatial memory in
the Morris water maze (Puumala et al., 1996, 1998). It is worth
noting that prazosin may have an inhibitory effect on overall
locomotion in the Morris water maze (Levcik et al., 2013), which
would confound the spatial memory test.
Genetic studies have revealed subtype specific roles for the α1
receptors with the α1A knockout mice showing themost dramatic
cognitive deficits. The α1Aknockout mice display poor spatial
learning and memory in both the Barnes maze and Morris water
maze (Doze et al., 2011). α1B knockout mice show increased
short-term-latency and a decline in long-term-latency in passive
avoidance tests, suggesting that the α1B receptor plays a role in
fear-motivated exploratory behavior (Nalepa et al., 2013). While
α1D knockout mice show no difference in spatial or emotional
learning when compared to WT mice (Sadalge et al., 2003), these
mice have a deficit in working memory and attention (Mishima
et al., 2004).
The α2 receptors are involved in several different paradigms of
learning. Antagonism of α2 receptors has been shown to benefit
memory and cognition in a number of settings. Yohimbine,
an α2 antagonist, increases fear conditioning (Gazarini et al.,
2013) and improves spatial cognitive performance in the Morris
water maze (Torkaman-Boutorabi et al., 2014). Additionally,
yohimbine effectively improves both accuracy and response
latencies in the habituated animal (Brown et al., 2012). Another
α2 antagonist, dexefaroxan, improves odor learning (Veyrac
et al., 2007), spatial and visual memory, and passive avoidance
(Chopin et al., 2002). The α2 antagonist atipamezole enhances
spatial learning in aged rats (Haapalinna et al., 2000). α2 receptor
blockademay also potentiate cholinergic activity in the formation
of a long-term memory trace; the α2 antagonists yohimbine,
idazoxan, and P86 7480 are all able to enhance passive avoidance
learning when co-administered with heptylphysostigmine, a
cholinesterase inhibitor (Camacho et al., 1996).
Pharmacological activation of the α2 receptors also leads to
cognitive changes. In a model of the effect of stress on spatial
learning, clonidine exacerbates the learning deficits produced
from the stress of cold water in the Morris water maze (Warner
and Drugan, 2012). Clonidine also weakens reconsolidation of
fear memories, and has therefore recently been looked at as
a potential treatment for PTSD (Gamache et al., 2012; Zoladz
et al., 2013). While activation of the α2A receptors induces
deficits in spatial and fear learning, it actually has been shown
to enhance working memory. Clonidine and guanfacine can
improve working memory in aged monkeys with documented
memory impairment (Arnsten and Goldman-Rakic, 1985, 1987;
Arnsten et al., 1988). It is known that working memory is
mainly localized to the prefrontal cortex (Wang et al., 2013c)
whereas spatial and fear memory involve the hippocampus
(Bird and Burgess, 2008). The difference in clonidine’s effects
on these different cognitive paradigms is likely due to diverse
functions of α2 receptors in regulating neurotransmission in
different brain regions. α2 receptor stimulation enhances firing of
prefrontal cortical neurons through inhibition of HCN channels
(Wang et al., 2007). On the other hand, α2 receptor activation
blocks hippocampal long-term plasticity (McMahon and Wang,
unpublished findings).
There is limited information on the role of the α2 receptors
in cognition from genetically modified mice. α2A(the most
prevalent subtype in the CNS) knockout mice show impairment
in working memory (Franowicz et al., 2002). Changes in spatial
or fear learning in these mice remain uninvestigated.
Much of our knowledge of the role of the β adrenergic
receptors in cognition comes from pharmacological studies.
Pharmacological activation of β receptors using the agonist
isoproterenol has been found to enhance long term potentiation
and memory consolidation in the hippocampus (Gelinas et al.,
2008). On the other hand, the β antagonist propranolol inhibits
memory retrieval in extinction tasks (Ouyang and Thomas,
2005) and in a fear conditioning paradigm (Taherian et al.,
2014). Propranolol also inhibits taste memory consolidation
(Ruetti et al., 2014) and impairs scent recall (Veyrac et al.,
2007). Additionally, administration of propranolol with
scopolamine, a muscarinic cholinergic antagonist, or with
p-chlorophenylalanine, a serotonergic antagonist, synergistically
impairs rat spatial learning in the Morris water maze (Decker
et al., 1990; Saber and Cain, 2003; Kenton et al., 2008). Together,
these studies indicate a positive role of β adrenergic receptors in
memory consolidation in general.
Effects of β1 and β2 subtype-selective ligands on cognition
have also been investigated. Infusion of the β2 agonist clenbuterol
into the amygdala facilitates memory retention in an inhibitory
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avoidance task (Introini-Collison et al., 1991), and infusion
of clenbuterol into the prefrontal cortex enhances trace fear
memory (Zhou et al., 2013). On the other hand, infusion of
β1 or β2 antagonists into the amygdala causes a deficit in
auditory fear memory (Qu et al., 2008). However, xamoterol, a
partial β1 receptor agonist, impairs the retrieval of hippocampus-
dependent spatial reference memory in rats (Schutsky et al.,
2011), suggesting that different subtypes of β receptors may play
different roles in regulating cognition in different brain regions.
Other Functions of the Noradrenergic
System Potentially Related to AD
It is well-established that the brains of AD patients have
significant neuroinflammation (Hensley, 2010). Both astrocytes
and microglia have adrenergic receptors present (Salm and
Mccarthy, 1989; Shao and Sutin, 1992; Sutin and Shao, 1992;
Tanaka et al., 2002), and norepinephrine regulates inflammatory
processes through these receptors. Loss of neurons in the locus
coeruleus and the subsequent loss of norepinephrine result in an
increase in inflammation in animal models (Heneka et al., 2006,
2010; Jardanhazi-Kurutz et al., 2011). Furthermore, stimulating
microglia with norepinephrine led to increased phagocytosis
of amyloid-β (Aβ) by microglia (Heneka et al., 2010). Taken
together, this indicates that alterations of the noradrenergic
system at least partially contribute to the neuroinflammation seen
in AD and the pathogenic consequences of that inflammation.
Another symptom of AD is aberrant glucose metabolism
(Schubert, 2005), which can be seen in the increased levels of
oxidative stress in AD patients that occurs before the appearance
of Aβ plaques (Perry et al., 2002). α1 receptors on astrocytes
regulate glucose uptake. Additionally, activation of the α2
receptors on astrocytes leads to an increase of glycogenesis,
whereas activation of the β -receptors promotes glycogenolysis
(O’donnell et al., 2012). This indicates that the adrenergic
receptors play a large role in the balance of glycogen in the
brain and, therefore, could potentially be targeted to improve the
aberrant glucose metabolism seen in AD.
Noradrenergic Changes in AD
There is considerable evidence showing that the normal anatomy
and functions of the noradrenergic system are altered in AD. We
will consider these data at the level of neurons, neurotransmitters,
and receptors.
Changes in Locus Coeruleus Neurons
At an anatomical level, it has been well-established that AD
patients show a loss of noradrenergic neurons in the locus
coeruleus (Mann et al., 1980; Iversen et al., 1983; Forstl et al.,
1994; Matthews et al., 2002; Zarow et al., 2003). Though there
is an overall loss in neurons, there is actually an increase
in both dendritic and axonal sprouting from the remaining
noradrenergic neurons in the locus coeruleus. In patients with
dementia, the dendritic sprouting from the locus coeruleus
to the prefrontal cortex after neuronal loss keeps the levels
of connections stable or even slightly increased, as measured
by presynaptic α2 and postsynaptic α1 receptor density (Szot
et al., 2007). Axonal sprouting of the remaining locus coeruleus
neurons to the hippocampus also occurs in patients with
noradrenergic neurodegeneration (Szot et al., 2006). Recently,
technological advances have allowed for the detection of locus
coeruleus neuron loss in living patients. Using high-resolution
fast spin-echo T1-weighted imaging, Takahashi et al. (Takahashi
et al., 2015) were able to detect a decrease in locus coeruleus
density in AD patients when compared to controls. This advance
is exciting as it could allow for the early detection of locus
coeruleus neuron loss, which occurs at early stages of AD.
While the noradrenergic changes are commonly seen in AD
patients, few commonly used AD mouse models actually show
the locus coeruleus degeneration. A Down syndrome mouse
model that includes a triplication of the APP gene shows
degeneration of the locus coeruleus neurons with aging, which
has been linked to the overexpression of APP (Salehi et al., 2009;
Lockrow et al., 2011). Tg2576 mice also display some degree of
noradrenergic changes, including neurodegeneration in the locus
coeruleus (Liu et al., 2008; Guerin et al., 2009; Eimer and Vassar,
2013). However, many other AD rodent models do not have
neurodegeneration, which is a limitation of these models.
Changes in Norepinephrine Levels
Despite the loss of the noradrenergic neurons, there have
been conflicting reports on levels of norepinephrine in the
brain, with some studies showing a decrease in norepinephrine
while others showing that norepinephrine levels in AD
patients remain constant, or even elevated. Using either HPLC
(Martignoni et al., 1992; Nazarali and Reynolds, 1992; Matthews
et al., 2002) or a fluorophore based method (Reinikainen
et al., 1988), several groups have found a decrease in
norepinephrine concentration in various brain regions, with the
loss proportional to the level of cognitive deficit (Matthews et al.,
2002). Norepinephrine turnover is increased in the remaining
locus coeruleus neurons. The concentration of 3-methoxy-4-
hydroxyphenylglycol (MHPG), a norepinephrine metabolite, has
been used to indicate the norepinephrine turnover rate. AD
patients have a higher ratio of the norepinephrine metabolite to
norepinephrine (Palmer et al., 1987; Hoogendijk et al., 1999).
This increased metabolism of norepinephrine is a possible cause
of the decreased norepinephrine levels. On the other hand, a
number of studies have shown no change in norepinephrine
levels in different brain regions or cerebrospinal fluid (CSF)
in both sporadic and familial AD cases (Sparks et al., 1988;
Herregodts et al., 1989; Tohgi et al., 1992). In addition, increased
norepinephrine levels were reported, which correlated with
decreased cognitive function (Tohgi et al., 1992) and aging (Elrod
et al., 1997) in AD patients.
There is evidence of compensatory changes that can
account for the loss in noradrenergic neurons, yet stable
or increased norepinephrine levels. One finding has been
that norepinephrine transporter sites are decreased in AD
patients. In autoradiograph studies (Gulyas et al., 2010) and
radioligand binding studies of post-mortem tissues (Tejani-
Butt et al., 1993), the norepinephrine transporter sites were
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significantly reduced in AD brains compared to normal control
samples. As norepinephrine transporter is responsible for
norepinephrine reuptake to the presynaptic neurons, a decrease
in norepinephrine transporter sites would increase the amount
of norepinephrine in the synapse. Another possible mechanism
for norepinephrine increase is an increase in the enzymes
responsible for the production of norepinephrine. Tyrosine
hydroxylase, which catalyzes the rate-limiting step in the
production of norepinephrine, is increased in the brain of AD
patients (Iversen et al., 1983; Szot et al., 2006, 2007). The enzyme
DβH is also increased in serum, CSF, and peripheral blood
lymphocytes in AD cases (Miyata et al., 1984; Giubilei et al.,
2004).
With researchers reporting both increases and decreases in
norepinephrine levels in AD patients, it is necessary to look
deeper into the discrepancy. The differences are likely due to
the stage of the disease and the brain’s ability to compensate for
the neuronal loss. One possible theory is that in the early stages
of locus coeruleus neuron loss, the remaining neurons undergo
compensatory mechanisms to maintain the norepinephrine level.
However, as the disease progresses and more neurons are
lost, it may become impossible for the remaining neurons to
totally compensate. It is also possible that the brain over-
compensates for the neuronal loss, which can account for the
increased norepinephrine levels reported in the later stages
of the disease. Eventually, however, if the disease progresses
enough, the loss of locus coeruleus neurons will be too great to
overcome and norepinephrine levels will decline. This hypothesis
could be tested by using the new high-resolution fast spin-echo
T1-weighted imaging to measure locus coeruleus density and
correlating it to the norepinephrine levels in the CSF of AD
patients (Takahashi et al., 2015).
Changes in Noradrenergic Receptors
In addition to the anatomical and neurotransmitter changes,
there are also changes to the adrenergic receptors of AD patients.
Changes in the receptors in postmortem brain tissues have been
studied using both binding assays and mRNA quantification.
These studies indicate several changes in the AD brain, which
would lead to altered functional outcome in response to
norepinephrine.
α1 receptor density has been examined using non-subtype
selective radioligands. Decreases in α1 receptor density have been
reported in the prefrontal cortex (Kalaria, 1989), hippocampus,
and cerebellum (Shimohama et al., 1986). However, when
examining subregions, Szot et. al. found stable to slightly
increased α1 binding sites in layers I/II of the prefrontal cortex
(Szot et al., 2007) and in the molecular layer of the dentate gyrus
of the hippocampus (Szot et al., 2006). Additionally, changes
in specific α1 receptor subtypes have been examined, with a
reduction of α1C mRNA in layers II/III of the prefrontal cortex
and a significant decrease in α1D mRNA in the hippocampus
(Szot et al., 2007).
The density of α2 receptors has also been studied by the use
of binding assays. Increased α2 receptor density has been found
in cortical membranes (Ruiz et al., 1993) and the dentate gyrus
granule cell layer (Szot et al., 2006) of post-mortem AD patient
brains and in brains of patients with the AD related disease,
dementia with Lewy bodies (Leverenz et al., 2001; Szot et al.,
2006). The levels of α2 receptors in brain microvessels, which
are innervated by locus coeruleus noradrenergic neurons (Kalaria
et al., 1989b), are also increased in AD patients (Kalaria et al.,
1989a). However, there are also reports of no significant change
(Shimohama et al., 1986; Szot et al., 2007) in α2 receptor density
in the cortex or a decrease in α2 density in the hippocampus
(Pascual et al., 1992) or nucleus basalis of Meynert (Shimohama
et al., 1986) of AD patients. One thing that could be contributing
to the discrepancy of the above reports is that studying α2
receptor density is a more complicated endeavor due to their
unique presence on the presynaptic neuron. This is especially true
considering the neuronal loss that occurs in the locus coeruleus
of AD patients, and the fact that α2 receptors are located on those
neurons. Therefore, even if there is actually an increased density
of α2 receptors on the remaining locus coeruleus neurons or at
the projection sites, locus coeruleus neuron loss could mask that
increase due to the lost receptors on the degenerated neurons.
Indeed, Szot et al. (2007) found that the loss of locus coeruleus
neurons was greater than the α2 receptor loss in the cortex
area with locus coeruleus neuron projections. This probably
indicates an increased number of receptors per neuron in AD
cases.
Changes in α2 receptor subtypes have also been examined in
AD patients. By measuring the mRNA at different projection
sites to isolate just the postsynaptic receptors, Szot et al. (2007)
found decreased levels of α2A mRNA in the prefrontal cortex,
though the reduction was limited to layer II. In the hippocampus,
levels of α2A mRNA were unchanged, but there was a significant
decrease in α2C mRNA. Szot et al. (2006) also looked at
presynaptic receptors in post mortem AD brains by measuring
receptor mRNA from the locus coeruleus and found an overall
reduction in α2AmRNA in AD patients without change in the
number of receptors per cell. While examination of mRNA levels
is useful to determine changes in different receptor subtypes, it
may not reflect actual changes in receptor density. Therefore,
these data should be interpreted with the results from the binding
assays.
Finally, β receptor density in AD patient brains has been
studied, though there is considerably less information on the
β receptor changes. In both AD patients and controls, the β1
receptor density is higher in the cortex than the hippocampus,
but there is no difference between the two groups (Lemmer
et al., 1993). However, a decrease in β2 receptor density
occurs in the microvessels of AD patients (Kalaria et al.,
1989a).
Pathological changes of the noradrenergic system in AD
are dynamic as the disease progresses. Most current studies
look at one snapshot of the pathological process, which likely
give discrepant results. Systematic examinations of various
noradrenergic components at different disease stages and
correlations of these changes with other AD-related pathological
and cognitive deficits are necessary in order to fully comprehend
noradrenergic dysfunction in AD.
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Potential Involvement of Noradrenergic
Dysregulation in AD Pathogenesis and
Progression
The Role of Norepinephrine
The first evidence for a functional role of noradrenergic
dysregulation in AD comes from animal models in which
the norepinephrine levels are manipulated. Treatment of AD
transgenic mice with DSP-4, a neurotoxin which selectively
ablates noradrenergic neurons, increases Aβ deposition (Heneka
et al., 2006; Kalinin et al., 2007; Jardanhazi-Kurutz et al.,
2010), impairs spatial memory (Jardanhazi-Kurutz et al., 2010)
and alters α1, α2, and β1 receptor binding sites and mRNA
expression (Jardanhazi-Kurutz et al., 2011). DSP-4 treatment
also increases the levels of accumulated hyperphosphorylated
tau in cortices of female APP-SL mice (Oikawa et al., 2010).
APP/PS1 mice crossed with DβH−/− mice, which are unable
to synthesize norepinephrine, have compromised LTP and maze
performance, which is worse than in either of the single mutants
alone (APP/PS1 or DβH−/−) (Hammerschmidt et al., 2013).
APP/PS1 mice crossed with Ear2−/− mice, which show marked
locus coeruleus neuron loss, have exacerbated LTP and memory
deficits, but do not have plaque deposition different from
APP/PS1 mice (Kummer et al., 2014). This indicates that the
norepinephrine loss contributes to the cognitive dysfunction of
AD, even in the absence of the hallmark pathogenic Aβ plaques.
Taken together, this evidence suggests that loss of noradrenergic
input to the cerebral cortex exacerbates AD-related pathological
and behavioral deficits.
In vivo tests also suggest that norepinephrine supplementation
could be beneficial in AD. Norepinephrine levels and microglial
function can be rescued by peripherally administering the
norepinephrine precursor, L-DOPS, in DSP-4 lesioned AD mice
expressing mutant APP (APP/PS1 or APPV717I). Additionally,
these same AD model mice have improved Aβ clearance,
decreased Aβ plaques, and improved spatial memory after L-
DOPS administration (Heneka et al., 2010; Hammerschmidt
et al., 2013). Co-administering L-DOPS along with atomoxetine,
a norepinephrine reuptake inhibitor, in 5xFAD transgenic mice
improves learning in the Morris water maze test (Kalinin et al.,
2012).
In addition to animal studies, human association studies
support the role of norepinephrine loss in AD. In AD patients,
the extent of noradrenergic degeneration correlates with both
the degree of pathological changes (including amyloid plaques
and neurofibrillary tangles) and the severity of cognitive deficits
(Bondareff et al., 1987; Zarow et al., 2003). Additionally, there is
a link between a low-activity polymorphism in the DβH gene and
AD in a Caucasian population (Combarros et al., 2010). As DβH
is required for the production of norepinephrine, lower activity
of this enzyme leads to decreased norepinephrine. However,
this polymorphism may be population-specific, as a study by
Komatsu et al. (2014) looked at that same polymorphism along
with another DβH polymorphism and did not find any link
between either of the two different DβH polymorphisms and AD
in a Japanese population.
Potential Involvement of the Noradrenergic
Receptors
The potential role of α1 receptors in modulating AD-related
pathological and behavioral changes has been studied using
prazosin, an α1 receptor antagonist. Prazosin reduces the
generation of Aβ in N2a cells and ameliorates memory loss
in APP23 transgenic mice (Katsouri et al., 2013). However,
since prazosin is not a subtype-selective antagonist, this
study only suggests the involvement of the α1 receptor
as a whole, and not the roles of the individual receptor
subtypes. Further studies are needed to determine the specific
subtypes of α1 receptors involved in the protective effect by
prazosin.
Our recent studies have revealed the involvement of the
endogenous α2A subtype receptor in AD pathogenesis (Chen
et al., 2014). Stimulation of the α2A receptor significantly
enhances, while genetic or pharmacological blockade of this
receptor reduces, Aβ generation and Aβ-related neuropathology.
Activation of α2A receptor signaling disrupts endogenous APP
interaction with sorting-related receptor with A repeat (SorLA),
and consequently promotes amyloidogenic processing of APP in
endosomes. We therefore provided the first evidence that SorLA-
dependent APP sorting can be targeted by extracellular signaling
to modulate amyloidogenesis. This is particularly important
because it suggests a method of reducing Aβ production
without targeting the activity of the secretases responsible for its
generation. Significantly, there have been reports of decreased
SorLA levels in late-onset AD patients (Scherzer et al., 2004)
and polymorphisms in the SorLA gene are linked to both
early and late-onset AD patients (Rogaeva et al., 2007; Grear
et al., 2009; Caglayan et al., 2012; Pottier et al., 2012). These
studies suggest that increasing the association between SorLA
and APP by inhibiting the α2A receptor could be beneficial
for many AD patients. In APP/PS1 mice, a clinically used α2
receptor antagonist, idazoxan, ameliorates AD-related cognitive
deficits in both novel object recognition and Morris water maze
tests (Chen et al., 2014). Consistently, fluparoxan, another α2
receptor antagonist, improves the spatial working memory in
a contextual fear conditioning task in these mice (Scullion
et al., 2011). In humans, increased α2A receptor density and/or
activity have been associated with type 2 diabetes mellitus and
depression (Cottingham et al., 2011; Cottingham and Wang,
2012), both of which are risk factors for AD. Under these
disease conditions, the increase in the α2A receptor may lead
to α2A receptor-promoted Aβ generation, which may act as a
key contributor driving AD-related pathophysiology. Elevated
α2 receptor density and response have also been reported in
living AD patients. One study has found an increase in the
α2 receptor density in platelets (Adunsky et al., 1989), and a
few have found that both AD patients and aged individuals
show increased norepinephrine levels in the CSF following
stimulation or inhibition of the α2 receptors (Peskind et al.,
1995; Raskind et al., 1999). Consistent with a role of the
α2A receptor promoting AD, our biostatistical analysis of the
National Alzheimer’s Coordinating Center database indicates
that chronic activation of the α2A receptor exacerbates disease
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progression in AD patients. Therefore, the α2A receptor
represents a previously unappreciated therapeutic target for
AD.
A role of β receptors in AD pathogenesis and progression
has also been suggested by pharmacological studies. The β1
blocker nevibolol reduces Aβ production in TG2576 mice
with established impairment, even though it does not improve
cognition function (Wang et al., 2013b). The β2 antagonist ICI
118,551 decreases Aβ load, while the β2 agonists isoproterenol
and clenbuterol increase it, in APP/PS1 mice (Ni et al., 2006).
Activation of the β2 receptor leads to increased trafficking
of γ secretase to the late endosomes and lysosomes due to
the association between β2 receptor and presenilin-1. The
production of Aβ in these organelles is subsequently increased.
Blockade of β2 receptors with ICI 118,551 also reduces Aβ
generation associated with stress in non-transgenic C57 mice
(Yu et al., 2010). However, in a 3xTg model of AD, ICI
118,551 increases Aβ levels and Aβ plaque burden as well
as exacerbates cognitive deficits (Branca et al., 2014). The
molecular mechanisms underlying the discrepancy of ICI
118,551 effects in different animal models remains to be
investigated. Another β blocker, propranolol, which blocks β1
and β2 receptors with equal affinity (Summers, 2006), has
been shown to lower BACE1 expression, decrease Aβ42 levels,
decrease tau hyperphosphorylation, and improve cognitive
impairments in both a mouse model of age-related cognitive
decline (SAMP8) or corticosterone-treated mice (Dobarro et al.,
2013a,b).
The β2 receptor can also mediate the effect of Aβ on tau
phosphorylation (Wang et al., 2013a). In APP/PS1mice, Aβ binds
to and activates the β2 receptors, which leads to an increase
in the activities of PKA and JNK. The β2-PKA-JNK pathway
results in hyperphosphorylation of tau at specific loci. While the
previous studies demonstrate that β agonists promote several
aspects of AD pathology, there is also evidence that β agonists
reduce, rather than promote, Aβ-related toxicity on neural
plasticity and cognition. A β2 agonist, terbutaline, prevents the
Aβ evoked inhibition of LTP (Wang et al., 2009b), and a β3
agonist, CL 316243, rescues Aβ induced memory loss in chicks
(Gibbs et al., 2010). Overall, β receptors appear to execute diverse
functions in multiple aspects related to AD pathology ranging
from Aβ metabolism to toxicity, and further studies are needed
to determine the role that each receptor subtype plays in the
mechanism of AD pathogenesis.
Human genetic studies have indicated association of the
β receptors with AD. A polymorphism in the β2 receptor
contributes to AD onset in a Chinese group (Yu et al., 2008).
Also, a combination of two single-nucleotide polymorphisms,
a T allele in the G-protein β3 subunit (GNB3) and a C allele
in the β2 adrenergic receptor (ADRB1), is associated with AD
susceptibility. This is likely through enhanced cAMP/PKA
signaling, which leads to an increase in APP expression (Bullido
et al., 2004). Furthermore, hypertension patients who were
taking beta blockers showed lower dementia incidence and
cognitive decline rate (Khachaturian et al., 2006; Rosenberg et al.,
2008), which suggests that blocking β receptors has a beneficial
effect on AD.
Summary and Perspectives
The role of the noradrenergic system in cognition has
long been known. Cognitive deficits occur after depletion
of norepinephrine and improvements in cognitive function
occur after increasing the availability of norepinephrine.
Norepinephrine elicits its effects through the nine adrenergic
receptors to which it binds. While the subtype-specific role of
each adrenergic receptor in cognition remains to be elucidated,
in general, α1 and β receptors are considered stimulatory,
enhancing neurotransmission and plasticity. On the other hand,
α2 receptors are inhibitory, reducing NE release and neuronal
excitability. In addition to the noradrenergic system being
important in cognitive function in normal circumstances, many
changes occur in the noradrenergic system in AD patients. The
degeneration of noradrenergic neurons in the locus coeruleus of
AD patients was an observation made over 30 years ago, and
more recent research has found changes that occur within the
remaining neurons, likely as compensatory mechanisms. This
neuronal loss and the resultant compensatory mechanisms lead
to changes in the level of norepinephrine available in the brain,
which consequently affect cognitive functions. Evidence from
both animal and human studies suggest that loss of noradrenergic
input significantly exacerbates AD-related cognitive deficits.
Familial AD with mutations in genes encoding APP or PS1
accounts for less than 10% of AD. In contrast, late-onset sporadic
AD likely involves multiple genetic and environmental risk
factors that lead to disruption of amyloid homeostasis. The
pivotal role that the noradrenergic system plays in supporting
interactions with and responses to environmental stimuli, as
well as alterations of this system in the early stage of AD,
suggest a potential contribution of noradrenergic dysfunction
to AD pathogenesis. Supporting this notion, activation of α2A
and β2 receptors directly regulates Aβ generation. More studies
are needed to address the potential role of each adrenergic
receptor subtype in amyloid metabolism and tau pathogenesis.
The available receptor knockout mice for each subtype (Philipp
and Hein, 2004) provide useful tools to address this. Genetic
studies could also be done to look for any polymorphisms
within the adrenergic receptor genes that are associated with
late-onset AD.
Despite the fact that a clear picture of the roles of various
noradrenergic components in AD pathogenesis is still lacking,
current evidence points to the α2A receptors as a novel
target for AD. This receptor subtype is the key regulator
of the noradrenergic activity, inhibiting both noradrenergic
input to the cerebral cortex and the resulting response
in this brain region (Hein, 2006). In addition, our recent
studies have demonstrated that activation of the α2 receptor
promotes amyloidogenic processing of the endogenous APP
and amyloid-related pathology (Chen et al., 2014). Therefore,
a pharmacological blockade of α2A receptors can both increase
NE release, which enhances NE-dependent cognitive and
neuroprotective effects, and decrease Aβ generation, which
reduces Aβ-dependent toxicity. Increased α2A receptor density
and/or activity have been observed in living AD patients and in
patients at high risk for AD, such as those with type 2 diabetes
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mellitus and depression. Blockade of α2A receptors would be
particularly effective in patients with these receptors upregulated.
While a novel target for AD, adrenergic receptors are an
established target for other disorders including cardiovascular,
behavioral, and mood disorders. Because of this, extensive drug
discovery research has already been done and a number of
noradrenergic receptor drugs, including α2 receptor blockers,
already exist and are FDA approved. Repurposing these drugs
could greatly expedite the timeframe for getting a novel AD
drug on the market. In fact, some noradrenergic drugs have been
tested in AD patients to alleviate some of the mood symptoms
associated with AD. For example, tricyclic antidepressants, which
block norepinephrine transporters, have been used to treat
depressed AD patients (Sallee and Pollock, 1990; Teri et al.,
1991), and both α1 and β receptor antagonists can improve
agitation in AD (Pauszek, 1991; Shankle et al., 1995; Peskind et al.,
2005; Wang et al., 2009a). While these noradrenergic drugs are
effective in the treatment of the behavioral and mood disorders
associated with AD, further research is needed to elucidate their
effect on cognition. Once this is known, it will be possible to
quickly repurpose these drugs in order to treat the cognitive
aspects of AD.
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